Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Head & Neck 1

Conditions

Neoplasms 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma of Lung 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 13Nivolumab 6Docetaxel 6cemiplimab 5avelumab 5atezolizumab 5Trastuzumab 5Carboplatin 4durvalumab 3Polymerase Chain Reaction 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorouracil 3Cisplatin 3Biopsy 3zimberelimab 2utomilumab 2ulixertinib 2tisotumab vedotin 2pertuzumab 2palbociclib 2belinostat 2amminedichloro(2-methylpyridine)platinum(II) 2Tetrahydrouridine 2Radiotherapy 2Radiosurgery 2Oxaliplatin 2Nicotine 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Rogaratinib × Head & Neck × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡